ATE138784T1 - Impfstoffe enthaltende avirulente phop-type mikroorganismen - Google Patents

Impfstoffe enthaltende avirulente phop-type mikroorganismen

Info

Publication number
ATE138784T1
ATE138784T1 AT90905859T AT90905859T ATE138784T1 AT E138784 T1 ATE138784 T1 AT E138784T1 AT 90905859 T AT90905859 T AT 90905859T AT 90905859 T AT90905859 T AT 90905859T AT E138784 T1 ATE138784 T1 AT E138784T1
Authority
AT
Austria
Prior art keywords
phop
avirulent
microorganisms containing
type microorganisms
containing vaccines
Prior art date
Application number
AT90905859T
Other languages
English (en)
Inventor
Roy Curtiss Iii
Jorge Galan
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23296173&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE138784(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of ATE138784T1 publication Critical patent/ATE138784T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01011—Aspartate-semialdehyde dehydrogenase (1.2.1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT90905859T 1989-03-31 1990-03-23 Impfstoffe enthaltende avirulente phop-type mikroorganismen ATE138784T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33197989A 1989-03-31 1989-03-31

Publications (1)

Publication Number Publication Date
ATE138784T1 true ATE138784T1 (de) 1996-06-15

Family

ID=23296173

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90905859T ATE138784T1 (de) 1989-03-31 1990-03-23 Impfstoffe enthaltende avirulente phop-type mikroorganismen

Country Status (10)

Country Link
US (1) US5424065A (de)
EP (1) EP0465560B1 (de)
JP (1) JP3004049B2 (de)
AT (1) ATE138784T1 (de)
AU (1) AU645489B2 (de)
CA (1) CA2013573C (de)
DE (1) DE69027313T2 (de)
DK (1) DK0465560T3 (de)
ES (1) ES2090129T3 (de)
WO (1) WO1990011687A1 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8912330D0 (en) * 1989-05-30 1989-07-12 Wellcome Found Live vaccines
AU6737190A (en) * 1989-11-03 1991-05-31 Washington University Cross-protective salmonella vaccines
DE69133219T2 (de) * 1990-11-09 2004-02-12 Washington University Avirulente salmonella mikroben mit einer mutation in dem cdt gen und ihre verwendung
US5599537A (en) * 1990-12-18 1997-02-04 The General Hospital Corporation Salmonella virulence genes
US5695983A (en) * 1990-12-18 1997-12-09 The General Hospital Corporation Salmonella vaccines
US5843426A (en) * 1990-12-18 1998-12-01 The General Hospital Corporation Salmonella vaccines
CA2097931C (en) * 1990-12-18 2003-07-29 Samuel I. Miller, Iii Salmonella vaccines
US6793927B1 (en) 1993-12-06 2004-09-21 The United States Of America As Represented By The Secretary Of The Department Of Agriculture Construction of Pasteurella haemolytica vaccines
US5587305A (en) * 1993-12-06 1996-12-24 The United States Of America As Represented By The Department Of Agriculture Pasteurella haemolytica transformants
US5922583A (en) * 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
US6861247B1 (en) 1995-11-14 2005-03-01 The General Hospital Corporation Salmonella secreted proteins and uses thereof
US5925354A (en) * 1995-11-30 1999-07-20 Michigan State University Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae
US6010705A (en) * 1997-04-11 2000-01-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Attenuated, invasive vaccines against fish pathogens
WO1999043839A1 (en) 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
US6713073B1 (en) * 1998-07-24 2004-03-30 Megan Health, Inc. Method of vaccination of newly hatched poultry
US6004815A (en) 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
CA2366462C (en) * 1998-12-04 2011-08-09 University Of Manitoba Two-step immunization procedure against chlamydia infection
US20020068068A1 (en) * 1999-02-02 2002-06-06 Mahan Michael J. Method of creating antibodies and compositions used for same
EP1168918A4 (de) * 1999-03-03 2002-08-21 Univ Pennsylvania Impfstoff- und gentherapiezusammensetzungen und verfahren zu ihrer herstellung und verwendung
AU779395B2 (en) 1999-04-30 2005-01-20 Institut De Recherche Cliniques De Montreal (Ircm) Mutant human CD80 and compositions for and methods of making and using the same
US6780405B1 (en) * 2000-04-28 2004-08-24 Avant Immunotherapeutics, Inc. Regulated antigen delivery system (RADS)
BR0112486A (pt) * 2000-07-14 2004-12-07 Univ Pennsylvania Poliproteìna, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição farmacêutica, e, método para imunizar um indivìduo contra hiv
CA2425152A1 (en) 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
US6872547B1 (en) 2000-10-11 2005-03-29 Washington University Functional balanced-lethal host-vector systems
US20040137003A1 (en) * 2001-04-30 2004-07-15 Curtiss Iii Roy Regulated antigen delivery system (rads)
WO2002100317A2 (en) 2001-05-25 2002-12-19 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
ES2192949B1 (es) * 2001-07-31 2004-08-16 Universidad De Zaragoza. Disminucion de la virulencia de mycobacterium tuberculosis por la inactivacion del gen phop.
US20050180985A9 (en) * 2001-10-04 2005-08-18 Vladoianu Ion R. Live attenuated salmonella strains for producing monovalent or multivalent vaccines
EP2380440B1 (de) 2002-04-15 2016-03-09 Washington University Geregelte Abschwächung von lebenden Impfstoffen zur Verbesserung der gekreuzten Schutzimmunogenität
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
CA2529051A1 (en) 2003-06-13 2004-12-29 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
AU2004296394A1 (en) * 2003-12-09 2005-06-23 Avant Immunotherapeutics, Inc. Orally-administered live bacterial vaccines for plague
WO2007050095A2 (en) 2004-11-19 2007-05-03 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
ES2374458T3 (es) * 2006-01-13 2012-02-16 The Trustees Of The University Of Pennsylvania Vacunas y agentes inmunoterapéuticos que utilizan il-15 optimizada en codones, y métodos para utilización de los mismos.
EP1981905B1 (de) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia-impfstoff
US8802419B2 (en) 2006-03-02 2014-08-12 University Of Massachusetts Modified pathogens for use as vaccines
WO2008014521A2 (en) 2006-07-28 2008-01-31 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2009025888A2 (en) 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
EP2152883A4 (de) * 2007-05-10 2010-10-27 Univ Arizona Rekombinante bakterien mit vektoren zur expression von nukleinsäuresequenzencodierenden antigenen
WO2009046449A1 (en) 2007-10-05 2009-04-09 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
CA2720168C (en) 2008-04-04 2024-04-30 David B. Weiner Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same
CN107083391A (zh) * 2008-04-04 2017-08-22 宾夕法尼亚大学托管会 屈曲病毒蛋白共有序列、编码该屈曲病毒蛋白共有序列的核酸分子和组合物及其使用方法
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US8921536B2 (en) 2008-10-29 2014-12-30 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
JP5753090B2 (ja) 2008-10-29 2015-07-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改良型ｈｃｖワクチンおよびその使用方法
US20110287520A1 (en) * 2008-11-20 2011-11-24 Heiko Apfel Salmonella marker vaccine
US9050287B2 (en) 2009-01-23 2015-06-09 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
CA2653478A1 (en) * 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
US9163219B2 (en) 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
GB2483595B (en) 2009-05-22 2017-03-29 The Arizona Board Of Regents For And On Behalf Of Arizona State Univ Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
KR20120093163A (ko) 2009-09-14 2012-08-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｉｌ-15 수용체 알파 및/또는 이를 인코딩하는 핵산 분자를 포함하는 백신 및 면역 치료제, 및 이를 이용하는 방법
US9109014B2 (en) 2009-11-02 2015-08-18 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
EP2526185A4 (de) 2010-01-22 2013-07-24 Univ Arizona Bakterium mit einer regulierten rfah-nukleinsäure
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
KR101784177B1 (ko) 2010-02-08 2017-10-11 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｒａｎｔｅｓ를 암호화하는 핵산 분자, 그리고 이를 포함하는 조성물 및 이의 사용 방법
US9598697B2 (en) 2010-05-28 2017-03-21 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
WO2012003460A2 (en) 2010-07-02 2012-01-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Compositions and methods for bacterial lysis and neutral lipid production
AU2011325893B2 (en) 2010-11-12 2016-01-14 Inovio Pharmaceuticals, Inc Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
US9243041B2 (en) 2011-01-31 2016-01-26 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
PT2672992T (pt) 2011-02-11 2020-07-27 Univ Pennsylvania Molécula de ácidos nucleicos codificando proteína nuclear do vírus da hepatite b e vacina compreendendo a mesma
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
CA2841852C (en) 2011-07-11 2020-06-30 Inovio Pharmaceuticals, Inc. Cross-protective arenavirus vaccines and their method of use
CN107723299B (zh) 2011-10-12 2022-02-01 宾夕法尼亚大学理事会 用于人乳头状瘤病毒的疫苗及其使用方法
KR101913674B1 (ko) 2011-10-24 2018-10-31 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 hcv 백신 및 이것을 사용하는 방법
KR20240096837A (ko) 2011-12-12 2024-06-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
JP6407028B2 (ja) 2011-12-12 2018-10-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用
KR20140146651A (ko) 2012-04-10 2014-12-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 인간 호흡기 합포체 바이러스 공통 항원, 핵산 컨스트럭트 및 이들로부터 제조된 백신, 및 이들을 사용하는 방법
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
WO2014165291A1 (en) 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Improved vaccines for human papilloma virus and methods for using the same
MX369709B (es) 2013-03-15 2019-11-19 Univ Pennsylvania Vacunación mejorada contra tirosinasa.
CA2895806C (en) 2013-03-15 2023-02-21 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
RU2751252C1 (ru) 2017-12-13 2021-07-12 Иновио Фармасьютикалз, Инк. Мезотелин-нацеленные вакцины от рака и их применение
RU2021115092A (ru) 2017-12-13 2022-01-24 Иновио Фармасьютикалз, Инк. Противораковые вакцины нацеленные на prame и их применения
CA3083531A1 (en) 2017-12-13 2019-06-20 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting boris and uses thereof
MX2020006217A (es) 2017-12-13 2020-12-03 Inovio Pharmaceuticals Inc Vacunas de cáncer dirigidas a muc16 y sus usos.
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen

Also Published As

Publication number Publication date
EP0465560B1 (de) 1996-06-05
DK0465560T3 (da) 1996-10-28
EP0465560A1 (de) 1992-01-15
WO1990011687A1 (en) 1990-10-18
AU645489B2 (en) 1994-01-20
CA2013573C (en) 1999-01-19
DE69027313D1 (de) 1996-07-11
JP3004049B2 (ja) 2000-01-31
AU5356090A (en) 1990-11-05
EP0465560A4 (en) 1992-04-08
ES2090129T3 (es) 1996-10-16
DE69027313T2 (de) 1997-01-23
US5424065A (en) 1995-06-13
CA2013573A1 (en) 1990-09-30
JPH04504204A (ja) 1992-07-30

Similar Documents

Publication Publication Date Title
ATE138784T1 (de) Impfstoffe enthaltende avirulente phop-type mikroorganismen
Mulder et al. Identification of additional virulence determinants on the pYV plasmid of Yersinia enterocolitica W227
Pridmore et al. The genome sequence of the probiotic intestinal bacterium Lactobacillus johnsonii NCC 533
Galán Molecular genetic bases of Salmonella entry into host cells
Harwood Bacillus
DE69128893D1 (de) Genetische veränderung von endothelzellen
ATE181572T1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
ATE219948T1 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
ATE321860T1 (de) Salmonella impfstoffe
DE69330518D1 (de) Dna, die aspartokinase iii-mutanten kodiert und ihre verwendung zur herstellung von l-threonin durch fermentation
FI903154A0 (fi) Kimeriska glykoproteiner innehaollande immunogeniska segment av glykoproteiner av maenniskans respiratory syncytial-virus.
WO1998056901A3 (en) Live attenuated vaccines
AR029622A1 (es) Una bacteria pasteurellaceae gram-negativa que comprende una mutacion en un gen, una composicion inmunogenica, una composicion de vacuna, un metodo para producir una mutante de dicha bacteria, un metodo para producir dicha bacteria atenuada, un polinucleotido purificado y aislado de la misma, un vec
Feunou et al. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1
DK1154791T3 (da) Neisseria-vaccinesammensætninger og fremgangsmåder
DK0556333T3 (da) Avirulente Salmonella mikrober, der omfatter en mutation i cdt genet, og anvendelser deraf
SE8104700L (sv) Eukaryotiskt autonomt replikerande segment
Sory et al. Yersinia enterocolitica O: 9 as a potential live oral carrier for protective antigens
Savelkoul et al. Invasion of HeLa cells by Bordetella bronchiseptica
Sato et al. gbpC and pac gene mutations detected in Streptococcus mutans strain GS‐5
D’Arienzo et al. Distinct immunomodulatory properties of Lactobacillus paracasei strains
Taichman et al. Suspected periodontopathic organisms alter in vitro proliferation of endothelial cells.
YU200091A (sh) Delecioni mutanti ahasarezistentni na herbicide
SE9401921D0 (sv) A method of cultivating bacteria
Curtiss et al. Vaccines containing avirulent phop-type microorganisms

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee